http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Parallel Rotated Exemplar-based Texture Synthesis
박한욱,김창헌 (사)한국컴퓨터그래픽스학회 2009 컴퓨터그래픽스학회논문지 Vol.15 No.1
We present a simple new idea to improve the quality of exemplar based texture synthesis using multiple rotated input exemplars. Our algorithm successfully obtain rotational synthesis feature variations and manages to reduce the artifacts in the results, especially patch seams due to the structure of the exemplars provided which have been inappropriate for previous neighborhood matching synthesis algorithms. Our algorithm is parallel in nature, thus it is possible to implement our algorithm using GPU or multi-core CPU to accelerate synthesis process.
박한욱(HanWook Park),변혜원(HaeWon Byun),김창헌(ChangHun Kim) 한국정보과학회 2011 정보과학회논문지 : 시스템 및 이론 Vol.38 No.4
본 논문에서는 다수의 예제로부터 텍스처를 합성하는 새로운 방법을 제안한다. 우리의 알고리즘은 다수 예제로의 확장에서 발생하는 예제 개수의 제한, 다수 텍스처간 다중 복합 전환(multi-way transition), 합성 시간의 과다 증가 등의 문제를 해결한다. 새로운 합성 방법은 전환용 이미지(transition image)와 인덱스 점핑(index jumping) 단계를 도입함으로써 텍스처간 복합 전환을 보이는 결과를 상호작용이 가능한 수준의 합성 시간에 생성한다. 제안된 방법은 복잡한 조작을 필요로 하지 않으며 반복성이 나타나지 않는 비동질적 합성 결과물을 생성 가능한 장점이 있으며, 실험 결과를 통해 이를 확인하였다. In this paper we present a novel method to generate a texture from multiple input exemplars. Our algorithm addresses issues of limitation on the number of input exemplars, multi-way transitions and maintaining parallelism extending the algorithm to handle multiple exemplars. By employing transition image and index jumping our algorithm can generate multi-way transition in reasonable synthesis time. Our approach does not require any special-case handling. We show usefulness of our algorithm by showing aperiodic inhomogeneous synthesis results.
강문철,박한욱,최동훈,최영우,박윤지,성영철,이승우 대한면역학회 2017 Immune Network Vol.17 No.6
Developing a novel vaccine that can be applied against multiple strains of influenza virus is of utmost importance to human health. Previously, we demonstrated that the intranasal introduction of Fc-fused IL-7 (IL-7-mFc), a long-acting cytokine fusion protein, confers long-lasting prophylaxis against multiple strains of influenza A virus (IAV) by inducing the development of lung-resident memory-like T cells, called TRM-like cells. Here, we further investigated the mechanisms of IL-7-mFc-mediated protective immunity to IAVs. First, we found that IL-7-mFc treatment augments the accumulation of pulmonary T cells in 2 ways: recruiting blood circulating T cells into the lung and expanding T cells at the lung parenchyma. Second, the blockade of T cell migration from the lymph nodes (LNs) with FTY720 treatment was not required for mounting the protective immunity to IAV with IL-7-mFc, suggesting a more important role of IL-7 in T cells in the lungs. Third, IL-7-mFc treatment also recruited various innate immune cells into the lungs. Among these cells, plasmacytoid dendritic cells (pDCs) play an important role in IL-7-mFc-mediated protective immunity through reducing the immunopathology and increasing IAV-specific cytotoxic T lymphocyte (CTL) responses. In summary, our results show that intranasal treatment with IL-7-mFc modulates pulmonary immune responses to IAV, affecting both innate and adaptive immune cells.
김새원,박한욱,김혜강,이승원,최소영,박윤지,이승우 대한면역학회 2019 Immune Network Vol.19 No.6
A full-length translational product of the trophinin gene, KIAA1114, is a distinctive marker of cancer stem cells in human hepatocellular carcinoma, and a mAb, Kiatomab, is specific to KIAA1114 antigen. In this study, we addressed the therapeutic potential of Kiatomab for treating both metastatic and solid tumors in mouse models. Kiatomab recognizes the linear epitope of KIAA1114, which is expressed on cell surfaces of various murine cancer cell lines. Kiatomab treatment induced potent antitumor responses in pulmonary metastasis models. Antitumor activity was mediated by the fragment crystallizable portion of Kiatomab and dependent on the host immune system. The use of Kiatomab alone as an antitumor therapy was ineffective in solid tumor models. However, in combination with cyclophosphamide, or by switching the isotype of the mAb, improved antitumor effects of Kiatomab were observed. These results suggest that Kiatomab can be used as a novel mAb for cancer immunotherapy.